Citius Pharmaceuticals 주식 (NASDAQ: CTXR)

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Things To Keep In Mind While Gifting Stocks

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/amd/earnings">closing bell on Tuesday, May 6.</a>
Analysts expect the Santa Clara, California-based company to report quarterly earnings at 93 cents per share, up from 62 cents per share in the year-ago period. AMD projects to report quarterly revenue at $7.12 billion, compared to $5.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Advanced Micro Devices, on April 9, announced the new Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud C4D and H4D virtual machines (VMs), which fifth-generation AMD EPYC processors power.
AMD shares gained 1.8% to close at $100.59 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/amd/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Ruben Roy maintained a Buy rating and cut the price target from $162 to $132 on April 28, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Susquehanna analyst Christopher Rolland maintained a Positive rating and cut the price target from $150 to $135 on April 24, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Wedbush analyst Matt Bryson maintained an Outperform rating and slashed the price target from $150 to $115 on April 23, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Bernstein analyst Stacy Rasgon maintained a Market Perform rating and cut the price target from $125 to $95 on April 22, 2025. This analyst has an accuracy rate of 71%.</li>
<li>UBS analyst Timothy Arcuri maintained a Buy rating and lowered the price target from $175 to $155 on April 17, 2025. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="613" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png" alt="" class="wp-image-902688" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-1024x613.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06035814/image-43.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45193793/top-3-tech-and-telecom-stocks-that-may-jump-this-quarter">Top 3 Tech And Telecom Stocks That May Jump This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Analyst Ratings

GOOG

GOOGL

Top Wall Street Forecasters Revamp AMD Motor Expectations Ahead Of Q1 Earnings

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

Reiteration

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>WestPark Capital analyst Curtis Shauger initiated coverage on Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy rating and announced a price target of $315. Workday shares closed at $248.34 on Monday. <a href="https://www.benzinga.com/quote/wday/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson initiated coverage on Broadridge Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Buy rating and announced a price target of $300. Broadridge Financial shares closed at $232.18 on Monday. <a href="https://www.benzinga.com/quote/br/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Matt Olney initiated coverage on FirstSun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with an Overweight rating and announced a price target of $44. Firstsun Capital Bancorp shares closed at $35.50 on Monday. <a href="https://www.benzinga.com/quote/fsun/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WDAY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-1024x570.png" alt="" class="wp-image-903111" style="width:672px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080929/image-54.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Initiation

FSUN

WDAY

This Workday Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.73) by 10.96 percent. This is a 44.64 percent decrease over losses of $(0.56) per share from the same period last year.

Earnings Misses

VERA

Vera Therapeutics Q1 EPS $(0.81) Misses $(0.73) Estimate

<a href="https://www.globenewswire.com/Tracker?data=bU_w34dgBvOq2j_Ai4IkIyvGeKLYYW3GNkjP-nGsC-2e2AY-Gv-G3xxySQLifClFaoUm0kd9V5G5AaGj6yWjgAG6V9aJz2xiGAcnviE2CRy2_IA2tON7BnEpHftb9W5bTFXJOotUhJJQ9tJdKvWoVQLWK-R3wLN1uIaUnhXJDG3JFyVl7wKdxfwtqvd5tf5K">IMUNON</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that data from the company's Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy in newly diagnosed patients with advanced epithelial ovarian cancer will be published in the peer-reviewed journal Gynecologic Oncology.
The review of full data, entitled: OVATION-2: A Randomized Phase I/II study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 gene therapy) with Neo/Adjuvant Chemotherapy in Patients Newly- Diagnosed with Advanced Epithelial Ovarian Cancer, is scheduled for publication on June 3, 2025.
As previously announced, data from the OVATION 2 study will also be reviewed in an oral presentation during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2025 in Chicago, Illinois. Premal H. Thaker, M.D., Interim Chief of Gynecologic Oncology, David &amp; Lynn Mutch Distinguished Professor of Obstetrics &amp; Gynecology, Director of&nbsp;Gynecologic Oncology Clinical Research&nbsp;at&nbsp;Washington University School of Medicine, is lead author on the publication and will lead the discussion in the oral presentation at the ASCO meeting.
"We are very pleased that the data from our OVATION 2 study will be presented in the highly esteemed peer-reviewed journal Gynecologic Oncology and in an oral presentation at the ASCO meeting," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "Having our data presented in two of the premier global platforms in gynecologic oncology underscores both the critical need to develop new therapies to treat ovarian cancer and the strength and potential of IMUNON's TheraPlas&#xAE; platform technology."
About the Phase 2 OVATION 2 Study
OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare NACT plus IMNN-001 versus standard-of-care NACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2&nbsp;in addition to NACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response.

Biotech

General

IMNN

IMUNON Announces Data From Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 In Combination With Neoadjuvant Chemotherapy In Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer. Will Be Published In Gynecologic Oncology

INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland
SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=3606414742&amp;u=https%3A%2F%2Fintensitytherapeutics.com%2F&amp;a=Intensity+Therapeutics%2C+Inc.">Intensity Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=2934215094&amp;u=https%3A%2F%2Fwww.sakk.ch%2Fen&amp;a=SAKK">SAKK</a> ("SAKK"), a&nbsp;decentralized&nbsp;academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Medicines Agency ("EMA") has authorized the initiation of the INVINCIBLE-4 (SAKK 66/22) ("INVINCIBLE-4 Study") (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=2042607023&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4227864-1%26h%3D1711039643%26u%3Dhttps%253A%252F%252Fwww.clinicaltrials.gov%252Fstudy%252FNCT06358573%253Fterm%253DINT230-6%2526rank%253D4%26a%3DNCT06358573&amp;a=NCT06358573">NCT06358573</a>)&nbsp;in France in collaboration with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418514-1&amp;h=1426838703&amp;u=https%3A%2F%2Fwww.unicancer.fr%2Fen%2F&amp;a=Unicancer">Unicancer</a>.
The INVINCIBLE-4 Study is a randomized open-label, multicenter study to determine the clinical activity, safety, and tolerability of INT230-6 in patients with early-stage, operable triple-negative breast cancer ("TNBC") who undergo standard of care neoadjuvant immunochemotherapy ("SOC") treatment and SOC alone. The primary endpoint is pathological complete response ("pCR") in the primary tumor and affected lymph nodes. Patients will be randomized one-to-one to receive a regimen of either two doses of INT230-6 followed by SOC, which consists of pembrolizumab, anthracyclines, carboplatin, cyclophosphamide, and paclitaxel (i.e., the Keynote-522 regimen), or the SOC alone. The study is already recruiting patients in Switzerland and is expected to enroll 54 patients.
 &nbsp;

INTS

Intensity Therapeutics and SAKK Secure EMA Approval To Initiate INVINCIBLE-4 Cancer Trial In France In Collaboration With Unicancer

Transaction adds proven HVAC solutions leader to ConnectM's expanding constellation of brands
MARLBOROUGH, Mass., May 6, 2025 /PRNewswire/ -- ConnectM Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) ("ConnectM" or the "Company"), a high-growth technology company powering the next generation of electrified equipment, mobility, and distributed energy, today announced the acquisition of all the assets of Air Temp Service Co. ("Air Temp"), a leading provider of heating and cooling solutions in New Jersey, in exchange for 1.5 million shares of ConnectM common stock.

CNTM

ConnectM Announces Acquisition Of Air Temp, Strengthening Owned Service Network, In Exchange For 1.5M Shares Of ConnectM Common Stock.

Legal

INMD

InMode Awarded Injunction And Damages For Counterfeit Sales Of Morpheus8 Radio Frequency Microneedling Devices And Needle Cartridges

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) affirms FY2025 sales outlook from $153.00 million-$163.00 million to $153.00 million-$163.00 million vs $157.27 million estimate.

Guidance

HRTX

Heron Therapeutics Affirms FY2025 Sales Guidance of $153.00M-$163.00M vs $157.27M Est

QphoX B.V., a Dutch quantum technology startup developing leading frequency conversion systems for quantum applications, Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>), a pioneer in full-stack quantum-classical computing, and the National Quantum Computing Centre (NQCC), the UK's national lab for quantum computing, today announced that they have been awarded a multinational grant to perform readout of superconducting qubits using light transmitted over optical fiber.
In a recent demonstration, QphoX and Rigetti validated the potential of this technique by optically reading out the state of a single superconducting qubit1. Optical readout is made possible by microwave-to-optical transduction at the base temperature of the cryostat. This transduction process converts the information contained in the microwave readout pulse into an optical signal carried over optical fiber. This approach could eventually replace conventional microwave amplifiers and coaxial wiring as part of the qubit signal processing chain and thereby offer considerable scaling advantages due to the comparatively low dissipation of the transducer and the negligible passive heat loads from telecommunications optical fiber.
QphoX, Rigetti and the NQCC are partnering to take the next step in this research to realize optical readout of a fully-fledged superconducting quantum computer. In this multinational collaboration, QphoX will scale its optical qubit readout system that will interface with Rigetti's 9-qubit Novera QPU, enabling optical&nbsp;readout of all qubits in the processor. The combined system will be installed and operated at the NQCC.
"Using light to&nbsp;readout the state of a superconducting qubit will remove a significant amount of heat load on cryogenic systems and therefore allow to overcome one of the critical bottlenecks in building a universal quantum computer. We are excited to take our developments to the next level and work with our partners in demonstrating this critical technology at scale," says Simon Groeblacher, CEO of QphoX.
"This innovative solution to a well-known scaling challenge is made possible by an open and modular system architecture," says Dr. Subodh Kulkarni, Rigetti CEO. "Integrating our partners' technology with our QPU enables us to benefit from even more expertise to accelerate our work towards fault tolerance."
"Demonstrating optical qubit readout at the system level represents an important step in our mission to advance scalable quantum computing, and we are delighted to host this collaborative work at the NQCC with such innovative project partners," commented Dr. Michael Cuthbert, Director of NQCC.
The 33-month program is funded by the Rijksdienst voor Ondernemend Nederland (RVO) and Innovate UK via the Eureka network, an intergovernmental organization for research and development funding and coordination.

Contracts

RGTI

QphoX, Rigetti And The National Quantum Computing Centre In The UK Enters Collaboration On Multi-Channel Optical Readout of Quantum Processors

<ul>
<li>BorgWarner's Dual-Clutch technology provides superior performance and increased transmission efficiency</li>
<li>New program captured with prominent transmission manufacturer</li>
<li>Program extended for seven years with a German OEM in China</li>
</ul>

BorgWarner Secures Two Dual-Clutch Transmissions Contract With Chinese Transmission Manufacturer; Extends Contract With German OEM In China

ARDX

Ardelyx Highlights Presentation At Digestive Disease Week 2025 Conference

<h3>Gainers</h3>
<ul>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares increased by 45.1% to $1.93 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.6 million. </li>
<li>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) stock increased by 23.87% to $5.5. The company's market cap stands at $625.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock rose 18.19% to $0.78. The market value of their outstanding shares is at $84.8 million. The company's, Q1 earnings came out today. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock moved upwards by 17.96% to $1.05. The market value of their outstanding shares is at $20.1 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) stock moved upwards by 15.62% to $7.92. The market value of their outstanding shares is at $2.1 billion. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares increased by 9.54% to $0.78. The company's market cap stands at $62.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock declined by 12.8% to $2.96 during Tuesday's pre-market session. The market value of their outstanding shares is at $12.4 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares fell 12.5% to $11.0. The company's market cap stands at $196.1 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock declined by 11.49% to $0.35. The market value of their outstanding shares is at $2.0 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares decreased by 9.85% to $0.9. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares decreased by 7.49% to $0.68. The market value of their outstanding shares is at $4.4 million. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares fell 6.78% to $0.27. The company's market cap stands at $38.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

EZGO

HOFV

JFBR

MKDW

NTCL

PRPL

TDUP

UCAR

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(1.40) by 0.71 percent. This is a 67.47 percent decrease over losses of $(0.83) per share from the same period last year.

Earnings Beats

CRBP

Corbus Pharmaceuticals Q1 EPS $(1.39) Beats $(1.40) Estimate

<h3>Gainers</h3>
<ul>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 83.1% to $2.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 48.22% to $2.09. The company's market cap stands at $28.7 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock moved upwards by 27.6% to $2.45. The company's market cap stands at $49.3 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock moved upwards by 16.59% to $0.75. The company's market cap stands at $2.8 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares rose 15.86% to $8.4. The market value of their outstanding shares is at $49.2 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares rose 14.63% to $1.4. The company's market cap stands at $163.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 46.4% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) shares fell 19.66% to $11.2. The market value of their outstanding shares is at $265.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 16.76% to $0.4. The market value of their outstanding shares is at $9.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares declined by 12.6% to $2.36. The company's market cap stands at $140.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 12.26% to $0.16. The market value of their outstanding shares is at $4.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 10.98% to $0.34. The market value of their outstanding shares is at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALDX

ATRA

BIAF

CAMP

EKSO

GCTK

KTTA

NCNA

SXTC

TCMD

TLSA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares moved upwards by 14.4% to $0.47 during Tuesday's pre-market session. The company's market cap stands at $5.9 million. </li>
<li>Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) shares rose 12.53% to $14.99. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) stock increased by 12.29% to $13.06. The market value of their outstanding shares is at $687.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock moved upwards by 10.31% to $0.49. The company's market cap stands at $48.2 million. </li>
<li>Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares rose 10.14% to $5.43. The market value of their outstanding shares is at $828.1 million. The company's, Q1 earnings came out today. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares rose 6.55% to $0.38. The market value of their outstanding shares is at $11.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) stock decreased by 20.1% to $4.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $381.8 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) stock fell 18.15% to $2.53. The company's market cap stands at $36.0 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares declined by 17.17% to $6.42. The market value of their outstanding shares is at $9.8 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock declined by 12.27% to $0.56. The market value of their outstanding shares is at $8.3 million. </li>
<li>JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock fell 9.46% to $1.15. The market value of their outstanding shares is at $6.0 million. </li>
<li>Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) stock fell 7.63% to $36.1. The company's market cap stands at $4.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRC

ARRY

ENGS

GPUS

JCSE

JELD

KRMN

UGRO

UPWK

VSTE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.
Shares of Ichor Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results and issued second-quarter <a href="https://www.benzinga.com/quote/ICHR/earnings">guidance below estimates</a>.
Ichor Hldgs reported quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $244.47 million which missed the analyst consensus estimate of $244.95 million.
Ichor Holdings shares dipped 14.8% to $17.75 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Hyperscale Data, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>) dipped 17.2% to $6.42 in pre-market trading. Hyperscale Data shares jumped 466% on Monday after the company issued FY25 sales guidance.</li>
<li>Immutep Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) fell 13.3% to $2.16 in pre-market trading. Immutep shares jumped over 45% on Monday after the company provided updates for cohort B of its Tacti-003 Phase IIb trial.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) fell 8.4% to $113.45 in pre-market trading. Palantir reported in-line earnings for its first quarter on Monday. Palantir reported first-quarter revenue of $883.86 million, beating analyst estimates of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates. The company also raised its full-year guidance.</li>
<li>Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) fell 7.7% to $17.30 in pre-market trading following downbeat quarterly earnings.</li>
<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) fell 7.1% to $8.31 in pre-market trading.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) fell 6.8% to $206.00 in today's pre-market trading after the company reported third-quarter results and issued fourth-quarter guidance with its midpoint below estimates.</li>
<li>EverQuote, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) declined 5.1% to $25.00 in pre-market trading following first-quarter results.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) fell 5% to $475.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

CSTL

EVER

ICHR

IMMP

PLTR

RCUS

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) stock increased by 132.2% to $1.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.6 million. </li>
<li>Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) shares increased by 36.05% to $42.79. The company's market cap stands at $822.6 million. </li>
<li>SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) stock rose 10.66% to $14.3. The market value of their outstanding shares is at $844.2 million. As per the press release, Q1 earnings came out today. </li>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) stock moved upwards by 8.76% to $10.55. The company's market cap stands at $3.7 billion. </li>
<li>Bridgeline Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) stock rose 8.1% to $2.2. The market value of their outstanding shares is at $22.9 million. </li>
<li>Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) stock moved upwards by 7.6% to $56.05. The market value of their outstanding shares is at $1.8 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) shares declined by 17.1% to $8.92 during Tuesday's pre-market session. The company's market cap stands at $179.4 million. </li>
<li>Ichor Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) stock declined by 14.9% to $17.74. The company's market cap stands at $603.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock fell 12.86% to $0.4. The company's market cap stands at $15.0 million. </li>
<li>Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) shares fell 9.16% to $10.22. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. </li>
<li>Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares fell 7.79% to $114.14. The market value of their outstanding shares is at $269.3 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) shares decreased by 7.36% to $23.16. The company's market cap stands at $307.0 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACLS

BLIN

FARO

JAMF

LDTC

MRIN

PONY

SEDG

TBCH

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysis</li>
<li>Clinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rate</li>
<li>Elraglusib/GnP combination arm demonstrated a favorable risk-benefit profile</li>
<li>Topline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting</li>
<li>Company plans to work with regulators to expeditiously bring elraglusib to commercialization</li>
</ul>
CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results from its ongoing Phase 2 (Actuate-1801 Part 3B) trial in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).&nbsp;&nbsp;
The topline results, which demonstrate a substantial improvement in median overall survival benefit in the elraglusib/GnP combination arm compared to the results announced in December 2024, will be presented on May 31, 2025, at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

ACTU

Actuate Therapeutics: Elraglusib In Combination With GnP Meets Primary Endpoints, Achieves Statistical Significance In Topline Results From Ongoing Phase 2 Trial In First-Line Treatment Of mPDAC

<ul>
<li>BorgWarner to supply Exhaust Gas Recirculation (EGR) components for OEM's passenger and light commercial vehicle platforms for combustion and hybrid applications</li>
<li>EGR system reduces NOx emissions and improves fuel economy to help meet environmental standards</li>
<li>EGR production extends through 2029</li>
</ul>

BorgWarner Extends Four Exhaust Gas Recirculation Contracts With North American OEM; Financial Terms Not Disclosed

Stock Split

Press Releases

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다.
1. 셀 사이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) 
벤징가 프로 데이터에 따르면 셀 사이는 5백만 달러 규모 공모에 대해 1,614만 보통주 가격을 주당 31센트로 책정했다. 주가는 시간외 거래에서 8.6% 하락한 0.55달러를 기록했다.
2. CCSC 테크놀로지 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) 
CCSC 테크놀로지는 9월 30일 종료된 6개월 동안 70만 달러의 순손실을 기록했고, 전년 동기 순이익은 40만 달러였다. 같은 기간 매출은 전년 동기 대비 22.9% 증가한 920만 달러를 기록했다. 주가는 시간외 거래에서 49.4% 상승한 2.45달러였다.
3. 루나 이노베이션스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) 
루나 이노베이션스는 이사회 멤버인 파멜라 코(Pamela Coe)가 은퇴할 것이라고 발표했다. 주가는 시간외 거래 세션에서 5.5% 하락한 2.05달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 시티우스 파마슈티컬스 (NASDAQ:<a href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR)</a> 
시티우스 파마슈티컬스는 9월 30일로 마감된 회계연도에 3,940만 달러(주당 5.97달러)의 순손실을 기록했으며, 전년 동기 순손실은 3,250만 달러(주당 5.57달러)였다. 주가는 시간외 거래 세션에서 1.9% 하락한 1.0207달러를 기록했다.
5. 지니어스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>)
지니어스 그룹의 상반기 매출은 전년 동기 1,180만 달러에서 490만 달러로 감소했다. 순자산은 2023년 12월 31일 기준 1,970만 달러에서 5,460만 달러로 177% 급증했다. 주가는 시간외 거래 세션에서 11.6% 상승한 0.72달러로 마감했다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Citius Pharmaceuticals

뉴스

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

월요일, 12월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌